Akorn, Inc. has added two injectable drug products to its API supply and margin sharing agreement with Natco Pharma. The two ANDA drug products are indicated for the prevention of nausea and vomiting associated with cancer chemotherapy. Under the agreement, signed April 2006, Natco will be responsible for the supply of API for both drug products and Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home healthca...